CSIMarket


Kezar Life Sciences Inc   (KZR)
Other Ticker:  
 


 

Kezar Life Sciences Inc

KZR's Financial Statements and Analysis



Kezar Life Sciences Inc increased first quarter of 2023 net loss per share of $-0.31 compare to net loss per share of $-0.26 recorded in the same quarter a year ago a decrease compare to $-0.20 realized in previous quarter.


first quarter of 2023
Earnings Per Share Revenues
$ -0.31 $  0 Mill
$-0.05     Unch.    



Kezar Life Sciences Inc 's Revenue fell by 0 % in first quarter of 2023 (Mar 31 2023) year on year, to $0 million and declined by sequentially.


Kezar Life Sciences Inc is Expected to report next financial results on August 10, 2023.

More on KZR's Income Statement



Kezar Life Sciences Inc 's in thefirst quarter of 2023 recorded net loss of $-22.199 million, an increase from net loss of $-16.024 million in I. Quarter a year ago.

Sequentially net loss advanced

More on KZR's Growth

Kezar Life Sciences Inc Inventories
In Mar 31 2023 company's net cash and cash equivalents decreased by $-4 million, capital expenditures grew by -34.00%, to $0 millions compare to same quarter a year ago and rose by -13.41% from IV. Quarter (Dec 31 2022).

More on KZR's Cash flow Statement


Kezar Life Sciences Inc does not pay out common stock dividend.

In trailing twelve-month period Kezar Life Sciences Inc payed $ -0.92 cash per share, on a free-cash flow basis .

Book value fell by -12.60 % sequentially to $3.49 per share, -50.02% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 3.49 per share from $ 3.99.

Company issued 4.76 million shares or 7.05 % in Mar 31 2023.


More on KZR's Dividends

 Market Capitalization (Millions) 210
 Shares Outstanding (Millions) 72
 Total Debt (Millions $) 10
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -74
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Kezar Life Sciences Inc does not pay out common stock dividend.

In trailing twelve-month period Kezar Life Sciences Inc had negative $ -0.92 cash flow per share, on a free-cash flow basis .

Book value fell by -12.60 % sequentially to $3.49 per share, -50.02% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 3.49 per share from $ 3.99.

Company issued 4.76 million shares or 7.05 % in Mar 31 2023.


More on KZR's Balance Sheets

 Market Capitalization (Millions) 210
 Shares Outstanding (Millions) 72
 Total Debt (Millions $) 10
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -74
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


Date modified: 2023-05-14T13:06:41+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071